Interferon-α in the generation of monocyte-derived dendritic cells: Recent advances and implications for dermatology

British Journal of Dermatology

Volumn 165, Issue 2, 2011, Pages 247-254

  Farkas, A ^a   Kemeny L ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIGEN; CALCITONIN; CD40 LIGAND; CHEMOKINE; COLONY STIMULATING FACTOR 1; CYTOKINE; DACARBAZINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 4; LIGAND; MELANOMA PEPTIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR LIGAND; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; AUTOIMMUNITY; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CELLULAR IMMUNITY; CHEMOTAXIS; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; INFECTION; INFLAMMATION; KIDNEY CARCINOMA; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MELANOMA; METASTASIS; MIXED LYMPHOCYTE REACTION; MONOCYTE; MONOCYTE DERIVED DENDRITIC CELL; NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TH1 CELL; THYROID MEDULLARY CARCINOMA;

CELL DIFFERENTIATION; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGE COLONY-STIMULATING FACTOR; MONOCYTES; PSORIASIS; SKIN DISEASES; SKIN DISEASES, VIRAL; SKIN NEOPLASMS; TOLL-LIKE RECEPTORS;

EID: 79960644751     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10301.x     Document Type: Review

References (50)

1. Banchereau J, Steinman RM,. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52. (Pubitemid 28155090)
2. Shortman K, Naik SH,. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007; 7: 19-30. (Pubitemid 46020824)
3. Sallusto F, Lanzavecchia A,. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-18.
4. Santini SM, Lapenta C, Santodonato L, et al. IFN-alpha in the generation of dendritic cells for cancer immunotherapy. Handb Exp Pharmacol 2009; 188: 295-317.
5. Paquette RL, Hsu NC, Kiertscher SM, et al. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 1998; 64: 358-67. (Pubitemid 28409243)
6. Radvanyi LG, Banerjee A, Weir M, Messner H,. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand J Immunol 1999; 50: 499-509. (Pubitemid 29503456)
7. Santini SM, Lapenta C, Logozzi M, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000; 191: 1777-88. (Pubitemid 30331574)
8. Parlato S, Santini SM, Lapenta C, et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 2001; 98: 3022-9.
9. Luft T, Luetjens P, Hochrein H, et al. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol 2002; 14: 367-80. (Pubitemid 34257764)
10. Padovan E, Spagnoli GC, Ferrantini M, et al. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol 2002; 71: 669-76.
11. Mohty M, Vialle-Castellano A, Nunes JA, et al. IFN-alpha skews monocyte differentiation into toll-like receptor 7-expressing dendritic cells with potent functional activities. J Immunol 2003; 171: 3385-93. (Pubitemid 37254538)
12. Santini SM, Di Pucchio T, Lapenta C, et al. A new type I IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells. Stem Cells 2003; 21: 357-62. (Pubitemid 36623176)
13. Gabriele L, Borghi P, Rozera C, et al. IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood 2004; 103: 980-7. (Pubitemid 38129560)
14. Farkas A, Tonel G, Nestle FO,. Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells. Br J Dermatol 2008; 158: 921-9. (Pubitemid 351521462)
15. Gigante M, Mandic M, Wesa AK, et al. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. J Immunother 2008; 31: 254-62. (Pubitemid 351441004)
16. Paquette RL, Hsu N, Said J, et al. Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia 2002; 16: 1484-9.
17. Trepiakas R, Pedersen AE, Met O, et al. Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. Vaccine 2009; 27: 2213-19.
18. Della BS, Nicola S, Riva A, et al. Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon-alpha. J Leukoc Biol 2004; 75: 106-16. (Pubitemid 38166785)
19. Gerlini G, Mariotti G, Chiarugi A, et al. Induction of CD83+CD14+ nondendritic antigen-presenting cells by exposure of monocytes to IFN-alpha. J Immunol 2008; 181: 2999-3008.
20. Carbonneil C, Saidi H, Donkova-Petrini V, et al. Dendritic cells generated in the presence of interferon-alpha stimulate allogeneic CD4+ T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells. Int Immunol 2004; 16: 1037-52. (Pubitemid 38960882)
21. Korthals M, Safaian N, Kronenwett R, et al. Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J Transl Med 2007; 5: 46.
22. Parlato S, Romagnoli G, Spadaro F, et al. LOX-1 as a natural IFN-alpha-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood 2010; 115: 1554-63.
23. Papewalis C, Jacobs B, Wuttke M, et al. IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol 2008; 180: 1462-70.
24. Lapenta C, Santini SM, Spada M, et al. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol 2006; 36: 2046-60. (Pubitemid 44251751)
25. Scutera S, Fraone T, Musso T, et al. Survival and migration of human dendritic cells are regulated by an IFN-alpha-inducible Axl/Gas6 pathway. J Immunol 2009; 183: 3004-13.
26. Bracci L, Schumacher R, Provenzano M, et al. Efficient stimulation of T cell responses by human IFN-alpha-induced dendritic cells does not require toll-like receptor triggering. J Immunother 2008; 31: 466-74.
27. Lehner M, Felzmann T, Clodi K, et al. Type I interferons in combination with bacterial stimuli induce apoptosis of monocyte-derived dendritic cells. Blood 2001; 98: 736-42.
28. Vermi W, Fisogni S, Salogni L, et al. Spontaneous regression of highly immunogenic molluscum contagiosum virus (MCV)-induced skin lesions is associated with plasmacytoid dendritic cells and IFN-DC infiltration. J Invest Dermatol 2011; 131: 426-34.
29. Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294: 1540-3. (Pubitemid 33063928)
30. Zhang Z, Maurer K, Perin JC, et al. Cytokine-induced monocyte characteristics in SLE. J Biomed Biotechnol 2010; 2010: 507475.
31. Ginhoux F, Tacke F, Angeli V, et al. Langerhans cells arise from monocytes in vivo. Nat Immunol 2006; 7: 265-73.
32. Mann A, Breuhahn K, Schirmacher P, et al. Keratinocyte-derived granulocyte-macrophage colony stimulating factor accelerates wound healing: stimulation of keratinocyte proliferation, granulation tissue formation, and vascularization. J Invest Dermatol 2001; 117: 1382-90. (Pubitemid 34032763)
33. Conti L, Gessani S,. GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances. Immunobiology 2008; 213: 859-70.
34. Szabo G, Dolganiuc A,. The role of plasmacytoid dendritic cell-derived IFN alpha in antiviral immunity. Crit Rev Immunol 2008; 28: 61-94. (Pubitemid 351264075)
35. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-9. (Pubitemid 47525141)
36. Ganguly D, Chamilos G, Lande R, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009; 206: 1983-94.
37. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.
38. Nestle FO, Di Meglio P, Qin JZ, et al. Skin immune sentinels in health and disease. Nat Rev Immunol 2009; 9: 679-91.
39. Figdor CG, de Vries IJ, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10: 475-80. (Pubitemid 38667904)
40. Steinman RM,. The control of immunity and tolerance by dendritic cell. Pathol Biol (Paris) 2003; 51: 59-60. (Pubitemid 36427570)
41. Banchereau J, Ueno H, Dhodapkar M, et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother 2005; 28: 505-16. (Pubitemid 41232572)
42. Trakatelli M, Toungouz M, Blocklet D, et al. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother 2006; 55: 469-74. (Pubitemid 43076899)
43. Di Pucchio T, Pilla L, Capone I, et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 2006; 66: 4943-51.
44. Papewalis C, Wuttke M, Jacobs B, et al. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm Metab Res 2008; 40: 108-16. (Pubitemid 351363421)
45. Nistico P, Capone I, Palermo B, et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer 2009; 124: 130-9.
46. Moschella F, Proietti E, Capone I, et al. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann NY Acad Sci 2010; 1194: 169-78.
47. Lee PY, Kumagai Y, Li Y, et al. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med 2008; 205: 2995-3006.
48. Belge KU, Dayyani F, Horelt A, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536-42. (Pubitemid 34250422)
49. Tatsugami K, Eto M, Harano M, et al. Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma. Int J Urol 2008; 15: 694-8.
50. Yoo C, Do HA, Jeong IG, et al. Efficacy of dendritic cells matured early with OK-432 (Picibanil), prostaglandin E2, and interferon-alpha as a vaccine for a hormone refractory prostate cancer cell line. J Korean Med Sci 2010; 25: 1284-90.